Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ZURA
- Price
- 6.45
- Stock movement up
- +0.13 (2.06%)
- Company name
- Zura Bio Limited Class A Ordinary Shares
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 419.40M
- Ent value
- 305.87M
- Price/Sales
- 209700.17
- Price/Book
- 3.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 260.34%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ZURA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 209700.17 |
| Price to Book | 3.54 |
| EV to Sales | 152937.17 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.02M |
| EPS (TTM) | -0.66 |
| FCF per share (TTM) | -0.57 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.00K |
| Gross profit (TTM) | -39.00K |
| Operating income (TTM) | -72.57M |
| Net income (TTM) | -62.52M |
| EPS (TTM) | -0.66 |
| EPS (1y forward) | -0.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1950.00% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 139.02M |
| Net receivables | 0.00 |
| Total current assets | 142.29M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 143.94M |
| Accounts payable | 3.27M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 25.49M |
| Total liabilities | 25.49M |
| Shareholder's equity | 118.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -53.36M |
| Capital expenditures (TTM) | 141.00K |
| Free cash flow (TTM) | -53.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -52.78% |
| Return on Assets | -43.44% |
| Return on Invested Capital | -52.78% |
| Cash Return on Invested Capital | -45.17% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.30 |
| Daily high | 6.63 |
| Daily low | 6.12 |
| Daily Volume | 1.61M |
| All-time high | 33.21 |
| 1y analyst estimate | 15.50 |
| Beta | 0.20 |
| EPS (TTM) | -0.66 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ZURA | S&P500 | |
| Current price drop from All-time high | -80.58% | -0.89% |
| Highest price drop | -97.00% | -56.47% |
| Date of highest drop | 28 May 2025 | 9 Mar 2009 |
| Avg drop from high | -87.23% | -10.84% |
| Avg time to new high | 178 days | 12 days |
| Max time to new high | 711 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
419.40M
Marketcap category
Small-cap
Description
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Employees
30
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page